Eribulin mesylate for the treatment of late-stage breast cancer

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 18, 2011, Pages 2883-2890

  Gourmelon, Carole ^a   Frenel, Jean Sébastien ^a   Campone, Mario ^a,b  

^a CENTRE RENÉ GAUDUCHEAU   (France)

^b Team 12   (France)

Author keywords

EMBRACE study; Eribulin mesylate; Halichondrin B; Metastatic breast cancer; Microtubule dynamics

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ERIBULIN; TAXANE DERIVATIVE;

ADVANCED CANCER; BREAST CANCER; CANCER SURVIVAL; DRUG MECHANISM; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; LEUKOPENIA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE;

ANIMALS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; FEMALE; FURANS; HUMANS; KETONES; MAXIMUM TOLERATED DOSE; MOLECULAR STRUCTURE; NEOPLASM STAGING; TREATMENT OUTCOME; TUBULIN MODULATORS;

EID: 81855172503     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.637490     Document Type: Review

References (32)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;12:69-90
2. Brewster AM, Hortobagyi GN, Broglio KR, et al. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst 2008;100:1179-83
3. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002;20:2812-23
4. Albain KS, Nag SM, Calderillo-Ruiz G, et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 2008;26:3850-7
5. Hirata Y, Uemura D. Halichondrins-antitumors polyether macrolides from a marine sponge. Pure Apll Chem 1986;58:701-10
6. Aicher TD, Buszek KR, Fang FG, et al. Total synthesis of halichondrin B and norhalichondrin B. Br J Am Chem Soc 1992;114:3162-4
7. Smith JA, Jordan MA. Determination of drug binding to microtubules in vitro. Methods Cell Biol 2010;95:289-99
8. Smith JA, Wilson L, Azarenko O, et al. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry 2010;49:1331-7
9. Towle MJ, Salvato KA, Budrow J, et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 2001;61:1013-21
10. Okouneva T, Azarenko O, Wilson L, et al. Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther 2008;7:2003-11
11. Towle MJ, Salvato KA, Wels BF, et al. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res 2011;71:496-505
12. Kutznetsov G, Towle MJ, Cheng H, et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrolcyclic ketone analog E7389. Cancer Res 2004;64:5760-6
13. Synold TW, Morgan RJ, Newman EM, et al. A phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: a California Cancer Consortium trial [abstract 3036]. J Clin Oncol 2005;23(Suppl):200
14. Goel S, Mita AC, Mita M, et al. A phase I study of eribulin mesylate (E7389) a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res 2009;15:4207-12
15. Tan AR, Rubin EH, Walton DC, et al. Phase I of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res 2009;15:4213-19
16. Eribulin mesylate. FDA Centers and Offices. Washington, DC: FDA/Center for Drug Evaluation and Research, 2010. Available from: http://www.fda.gov/ AboutFDA/CentersOffices/CDER/ ucm234527.htm [Last accessed 24 August 2011]
17. Zhang ZY, King BM, Pelletier RD, Wong YN. Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4. Cancer Chemother Pharmacol 2008;62:707-16
18. Devriese LA, Wandes J, Jenner A, et al. Eribulin mesylate pharmacocinetics in patients with solid tumors receiving repeated oral ketoconazole (KET) [abstract 574]. EORTC-AACR-NCI symposium; 16 - 19 November 2010. Available from: http://poster-submission. com/search/sresult [[Last accessed 24 August 2011]
19. Zheng W, Seletsky BM, Palme MH, et al. Structure-activity relationships of synthetic halichondrin B analog E7389: in vitro susceptibility to PgP-mediated drug efflux [abstract 2751]. Volume 7 Annual meeting of the American Association for Cancer Research 2003
20. Witteveen P, Marchetti S, Mergui-Roelvink M, et al. Eribulin mesylate pharmacokinetics in patients with hepatic impairment [abstract 2582]. J Clin Oncol 2010;28(Suppl):15
21. Jordan MA, Kamath K, Manna T, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 2005;4:1086-95
22. Mukohara T, Nagai S, Mukai H, et al. Eribulin mesylate in patients with refractory cancers: a Phase I study. Invest New Drugs 2011;published on line 02 September 2011; doi:10.1007/s10637-011-9741-2
23. Vahdat LT, Pruitt B, Fabian CJ, et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2009;7:2954-61
24. Cortes J, Vahdat L, Blum JL, et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 2010;28:3922-8
25. Aogi K, Iwata H, Masuda N, et al. A phase II study of eribulin in japanese patients with heavily pretreated metastatic breast cancer. Ann Oncol 2011;published on line 11 October 2011; doi:10.101093/annonc/mdr444
26. Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-labelrandomized study. Lancet 2011;377:914-23
27. Twelves C, Cortes J, Vahdat LT, et al. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clin Breast Cancer 2010;10:160-3
28. FDA approves new treatment option for late-stage breast cancer. FDA News and Events, Washington, DC: FDA/Press announcements, 2010. Available from: http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ ucm233863.htm [Last accessed 24 August 2011]
29. European Medecines Agency. Available from: http://www.ema.europa.eu [Last accessed 19 October 2011]
30. Clinicaltrials.gov, 2011 Available from: http://clinicaltrials.gov [Last accessed 24 August 2011]
31. Budman DR, Calabro A, Littlefield BA. Synergistic combinations of E7389 (halichondrin B analogue) with conventional agents: in vitro median effect analysis in cell lines with potential clinical implications [abstract 6055]. San Antonio Breast Cancer Symposium; 8 - 11 December 2004
32. Swami U, Chaudhary I, Ghalib MH, Goel S. Eribulin-A review of preclinical and clinical studies. Crit Rev Oncol Hematol 2011;published online 12 April 2011; doi:10.1016/j.critvonc.2011.03.002